FDA safety and drug updates in 2026 include expired levonorgestrel, Tazverik withdrawal, Tavneos liver injury concerns, carbidopa/levodopa vitamin B6 seizure warning, and GLP-1 label changes. Here is what patients need to know.
The latest FDA safety and drug update is not just another regulatory notice. It affects real patients, real prescriptions, and real decisions being made in pharmacies, clinics, and homes across the United States and around the world. In 2026, the U.S. Food and Drug Administration issued or highlighted several important medicine safety updates involving expired emergency contraception, cancer drug withdrawal, serious liver injury concerns, Parkinson’s medicines, and GLP-1 weight-loss drugs [1].
For readers in the USA, UK, Singapore, Canada, and Australia, this matters because FDA safety alerts often influence global medical conversations. However, medicine approvals, warnings, product names, and availability can differ by country. That is why patients should use FDA alerts as an early safety signal, but also check local regulators such as the UK MHRA, Singapore HSA, Health Canada, and Australia’s TGA when making country-specific decisions [8], [9], [10], [11].
Why this FDA drug safety update matters
Drug safety does not stop after a medicine is approved. The FDA continues monitoring medicines after they reach wider public use because rare or long-term side effects may appear after clinical trials. When new information is found, the agency can require label changes, issue safety communications, warn consumers, or support market withdrawal [1].
That is why this update deserves attention. It includes medicines used for very different needs: emergency contraception, cancer treatment, rare autoimmune disease, Parkinson’s disease, and weight management. Some updates involve urgent consumer action, while others involve a conversation with a doctor rather than immediate discontinuation.
Our platform’s value is simple: we do not just say “FDA issued a warning.” We explain who is affected, what changed, what the risk means in plain English, what patients should do next, and where to verify the official source.
Expired Amazon Basic Care Levonorgestrel: what consumers should check
The FDA warned consumers not to use expired Amazon Basic Care Levonorgestrel 1.5 mg after learning that several lots were delivered to purchasers after the labeled expiration date. The affected products were distributed between January 24, 2025, and April 29, 2026 [2].
Levonorgestrel 1.5 mg is an emergency contraceptive product, which makes timing and reliability especially important. The FDA advised consumers to check the expiration date on the product label, dispose of expired product appropriately, and contact a healthcare professional if they used an expired product [2].
This is where readers need practical guidance, not panic. If someone still has the product, the first step is to check the label. If the product is expired, it should not be used. If it was already used, the person should speak with a healthcare professional as soon as possible to discuss whether follow-up care is needed [2].
Tazverik withdrawal: why the FDA alert is serious
Another major FDA update involves Tazverik, also known as tazemetostat. The FDA alerted patients and healthcare providers that the sponsor planned to voluntarily withdraw Tazverik tablets from the U.S. market because of an increased rate of hematologic second primary malignancies. In plain English, this means new blood cancers were reported in some people who received Tazverik for a different cancer [3].
Tazverik was approved in 2020 for certain patients with metastatic or locally advanced epithelioid sarcoma and later for certain adults with relapsed or refractory follicular lymphoma. According to the FDA, newer trial data showed the rate of these second primary malignancies exceeded 5 percent over a median treatment duration of 15.8 months [3].
In the SYMPHONY-1 trial, 18 out of 318 patients treated with Tazverik developed hematologic second primary malignancies, while no cases were reported in the control arm. The FDA said most cases were myelodysplastic syndrome and acute myeloid leukemia, and some cases were serious, life-threatening, and fatal [3].
For patients, the key message is not to make a treatment decision alone. Anyone taking or recently treated with Tazverik should speak with their oncology team about individual risk, monitoring, and next steps.
Tavneos liver injury warning: symptoms patients should not ignore
Tavneos, also known as avacopan, is used with glucocorticoids and other standard-of-care medicines to treat adults with severe active ANCA-associated vasculitis. The FDA identified serious postmarketing cases of drug-induced liver injury associated with Tavneos, including fatal cases. Some cases involved vanishing bile duct syndrome, a condition that can damage bile ducts in the liver and may lead to permanent liver damage [4].
The FDA said patients should contact a healthcare professional immediately if they develop possible signs of liver injury. These include unusual tiredness, nausea, vomiting, unusual itching, light-colored stools, yellowing of the skin or eyes, dark urine, abdominal swelling, or pain in the right upper abdomen [4].
This is exactly where our platform can be different from many competitors. A reader does not only need to know that Tavneos has a liver warning. They need to know which symptoms matter, why early reporting matters, and why stopping or switching treatment should be done with medical guidance.
The FDA later said CDER proposed withdrawing approval of Tavneos because new information indicated the medicine had not been shown to be effective for its approved use and because the application that led to approval contained untrue statements of material fact. The FDA said Tavneos would remain on the market unless the applicant removes it or the FDA Commissioner mandates removal after the required process [5].
Carbidopa/levodopa warning: vitamin B6 deficiency and seizure risk
The FDA is requiring a new warning for drug products containing carbidopa/levodopa, which are widely used to treat symptoms of Parkinson’s disease. The warning states that these medicines can cause vitamin B6 deficiency and vitamin B6 deficiency-associated seizures [6].
Carbidopa/levodopa products include Crexont, Dhivy, Duopa, Rytary, Sinemet, Sinemet CR, Stalevo, and Vyalev. The FDA said healthcare professionals should evaluate baseline vitamin B6 levels before starting treatment, monitor levels periodically during treatment, and supplement vitamin B6 when necessary [6].
The FDA safety review identified 14 cases of seizures linked to vitamin B6 deficiency in patients using carbidopa/levodopa products. All reviewed cases involved levodopa doses above 1,000 mg daily, and two fatalities occurred in patients with documented low vitamin B6 levels and poorly controlled seizures [6].
For patients and caregivers, the useful takeaway is clear: do not stop Parkinson’s medication suddenly without medical advice, but ask a healthcare professional whether vitamin B6 testing is appropriate, especially if the patient is on a higher dose or has symptoms such as confusion, depression, numbness, tingling, sharp pain, muscle weakness, or seizures [6].
GLP-1 medication update: FDA removes suicide warning language
The FDA also requested removal of suicidal behavior and ideation warning language from the labeling of certain GLP-1 receptor agonist medicines used for weight reduction, including Saxenda, Wegovy, and Zepbound. The agency said a comprehensive review did not identify an increased risk of suicidal ideation or behavior with GLP-1 receptor agonist medications [7].
The FDA reviewed clinical trial data, postmarketing reports, observational studies, and data from the FDA Sentinel System. Its meta-analysis included 91 placebo-controlled GLP-1 trials involving 107,910 patients, and the results did not show an increased risk of suicidal ideation or behavior, anxiety, depression, irritability, or psychosis [7].
This update is important because GLP-1 medicines are among the most searched and discussed drugs globally. The FDA’s message is not that mental health symptoms should be ignored. The message is that the available evidence did not support a causal increased risk from these GLP-1 medicines. Patients should continue taking medication as prescribed and speak with a healthcare professional if they experience new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior [7].
How our coverage is different from competitors
Most FDA drug safety articles tell readers what happened. Our article tells them what to do with the information.
Official regulator pages are essential, but they can be technical. Breaking-news articles are useful, but many focus on only one drug. Some medical websites list alerts without explaining the reader’s next step. Our platform should combine the strengths of all three: official sourcing, news speed, and patient-friendly explanation.
The difference is our reader-first safety framework. Every FDA drug update we publish should answer five questions: What changed? Who is affected? What symptoms or risks matter? What should patients ask their doctor or pharmacist? Which official sources should readers check in their country?
That gives readers a reason to return. They are not coming only for headlines. They are coming because we turn complicated drug safety information into practical, verified, easy-to-read guidance.
Why readers should choose our platform
Readers should come to our platform because health updates can be confusing, and confusion can lead to two dangerous reactions: ignoring a real warning or panicking unnecessarily. Our job is to create the middle path: calm, clear, source-backed information that helps readers take the right next step.
For a patient, that may mean checking an expiration date, calling a pharmacist, recognizing symptoms of liver injury, asking about vitamin B6 testing, or understanding that a label change does not always mean a medicine is unsafe. For a caregiver, it may mean knowing which symptoms to watch for. For a healthcare professional, it may mean a fast plain-English summary with direct official references.
This is the value others often do not give. We do not only publish an FDA update. We translate the update into patient action, global relevance, and everyday decision-making.
What patients should do now
Patients should not stop, switch, or restart prescription medicines based only on a headline. FDA alerts are important, but individual decisions depend on diagnosis, dose, medical history, and available alternatives.
Anyone using a medicine mentioned in this update should check the official FDA source, contact a healthcare professional if the warning may apply, and report suspected side effects through the appropriate national reporting system. U.S. readers can report adverse events through FDA MedWatch, while readers in the UK, Singapore, Canada, and Australia should use their own national regulator’s reporting pathway [1], [8], [9], [10], [11].
The bottom line is simple: FDA drug safety updates are not just regulatory news. They are practical safety signals. The best response is to stay informed, verify the source, and get medical advice before making treatment decisions.
References
[1] FDA Drug Safety Communications. Official FDA page explaining drug safety communications and listing recent safety updates.
https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications
[2] FDA warning on expired Amazon Basic Care Levonorgestrel 1.5 mg. Explains the expired product issue, distribution dates, disposal advice, and MedWatch reporting.
https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-expired-amazon-basic-care-levonorgestrel-15-mg
[3] FDA alert on Tazverik voluntary withdrawal. Details the increased risk of new blood cancers and SYMPHONY-1 trial findings.
https://www.fda.gov/drugs/drug-alerts-and-statements/fda-alerts-health-care-providers-and-patients-about-increased-risk-new-blood-cancers-tazverik
[4] FDA Drug Safety Communication on Tavneos liver injury. Covers drug-induced liver injury, vanishing bile duct syndrome, symptoms, and monitoring advice.
https://www.fda.gov/drugs/drug-safety-communications/fda-identifies-cases-serious-liver-injury-patients-taking-tavneos-avacopan-severe-active-anti
[5] FDA CDER proposal to withdraw Tavneos approval. Explains the proposed withdrawal, efficacy concerns, and interim marketing status.
https://www.fda.gov/drugs/drug-alerts-and-statements/cder-proposes-withdraw-approval-tavneos
[6] FDA Drug Safety Communication on carbidopa/levodopa. Covers vitamin B6 deficiency, seizure risk, monitoring, and supplementation advice.
https://www.fda.gov/drugs/drug-safety-communications/fda-requiring-warning-about-vitamin-b6-deficiency-and-associated-seizures-drug-products-containing
[7] FDA Drug Safety Communication on GLP-1 receptor agonists. Explains FDA’s request to remove suicidal behavior and ideation warning language from Saxenda, Wegovy, and Zepbound labeling.
https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
[8] UK MHRA Drug Safety Update. Official UK source for medicine safety updates and healthcare professional safety information.
https://www.gov.uk/drug-safety-update
[9] Singapore Health Sciences Authority announcements. Official Singapore source for healthcare product safety alerts, recalls, and regulatory updates.
https://www.hsa.gov.sg/announcements
[10] Health Canada recalls and safety alerts. Official Canadian database for recalls, advisories, and safety alerts.
https://recalls-rappels.canada.ca/en
[11] Australia Therapeutic Goods Administration safety alerts. Official Australian source for therapeutic product safety alerts and possible medicine or medical device risks.
https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts
